Nebula Research & Development’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Nebula Research & Development’s Portfolio DCPH Stock Details DCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-67,645	Closed	-$1.06M	–	1094
2024 Q1	$1.06M	Buy	67,645 +3,486	+5%	+$53.7K	0.23%	126
2023 Q4	$1.03M	Buy	64,159 +30,990	+93%	+$395K	0.31%	74
2023 Q3	$422K	Buy	+33,169	New	+$458K	0.22%	174

Other funds holding DCPH

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Nebula Research & Development's DCPH Position: Q2 2024 in Review

Nebula Research & Development sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 67,645 shares — an estimated $1.06M sold.

Nebula Research & Development first reported a position in DCPH in Q3 2023 and held it in 3 quarters. The position peaked at $1.06M in Q1 2024. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.

Nebula Research & Development reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Nebula Research & Development sold 67,645 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $1.06M.
Nebula Research & Development first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2023 and held it in 3 quarters.
Nebula Research & Development's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $1.06M in Q1 2024.
1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Nebula Research & Development's 13F filing for Q2 2024, filed 14 Aug 2024.